| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1049824156 |
| P356 | DOI | 10.1038/SJ.ONC.1203431 |
| P698 | PubMed publication ID | 10713677 |
| P5875 | ResearchGate publication ID | 12601517 |
| P2093 | author name string | Ponzetto C | |
| Accornero P | |||
| Maritano D | |||
| Bonifaci N | |||
| P2860 | cites work | Sequence of MET protooncogene cDNA has features characteristic of the tyrosine kinase family of growth-factor receptors | Q24339620 |
| Crystal structure of the tyrosine kinase domain of the human insulin receptor | Q27730800 | ||
| Structure of the FGF receptor tyrosine kinase domain reveals a novel autoinhibitory mechanism | Q27733279 | ||
| Oncogenic RET receptors display different autophosphorylation sites and substrate binding specificities | Q28277591 | ||
| A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family | Q28285975 | ||
| Uncoupling of Grb2 from the Met receptor in vivo reveals complex roles in muscle development | Q28295203 | ||
| Scatter factor/hepatocyte growth factor is essential for liver development | Q28504542 | ||
| Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud | Q28506228 | ||
| Substitution of an aspartic acid results in constitutive activation of c-kit receptor tyrosine kinase in a rat tumor mast cell line RBL-2H3 | Q28579880 | ||
| Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog | Q29616450 | ||
| Catalytic specificity of protein-tyrosine kinases is critical for selective signalling | Q29616451 | ||
| The tyrosine kinase receptors Ron and Sea control "scattering" and morphogenesis of liver progenitor cells in vitro | Q30450983 | ||
| Receptor signaling: when dimerization is not enough | Q33723925 | ||
| A point mutation in the MET oncogene abrogates metastasis without affecting transformation. | Q33731936 | ||
| Dimerization mediated through a leucine zipper activates the oncogenic potential of the met receptor tyrosine kinase | Q34358610 | ||
| Activating mutations for the Met tyrosine kinase receptor in human cancer | Q36595980 | ||
| Uncoupling signal transducers from oncogenic MET mutants abrogates cell transformation and inhibits invasive growth | Q36734562 | ||
| The mutationally activated Met receptor mediates motility and metastasis | Q36735738 | ||
| Oncogenic mutation in the Kit receptor tyrosine kinase alters substrate specificity and induces degradation of the protein tyrosine phosphatase SHP-1 | Q37048166 | ||
| Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product | Q38315689 | ||
| Emerging multipotent aspects of hepatocyte growth factor | Q41066829 | ||
| Expression and characterization of biologically active human hepatocyte growth factor (HGF) by insect cells infected with HGF-recombinant baculovirus | Q41070311 | ||
| The Met receptor tyrosine kinase transduces motility, proliferation, and morphogenic signals of scatter factor/hepatocyte growth factor in epithelial cells | Q41563732 | ||
| "Invasive-growth" signaling by the Met/HGF receptor: the hereditary renal carcinoma connection. | Q41679360 | ||
| Autoregulatory mechanisms in protein-tyrosine kinases | Q41758716 | ||
| Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists | Q42810535 | ||
| Activating mutations in the Met receptor overcome the requirement for autophosphorylation of tyrosines crucial for wild type signaling | Q42810811 | ||
| Mechanism of met oncogene activation | Q42811433 | ||
| Novel mutations of the MET proto-oncogene in papillary renal carcinomas. | Q42815807 | ||
| Signaling requirements for oncogenic forms of the Met tyrosine kinase receptor. | Q42824006 | ||
| Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas | Q45345804 | ||
| Molecular cloning of a new transforming gene from a chemically transformed human cell line. | Q45345810 | ||
| Switching Signals On or Off by Receptor Dimerization | Q46100759 | ||
| Scatter factor protects epithelial and carcinoma cells against apoptosis induced by DNA-damaging agents | Q47801960 | ||
| Biological Activation of pro-HGF (Hepatocyte Growth Factor) by Urokinase Is Controlled by a Stoichiometric Reaction | Q57281116 | ||
| One gene—four syndromes | Q59096823 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1354-1361 | |
| P577 | publication date | 2000-03-01 | |
| P1433 | published in | Oncogene | Q1568657 |
| P1476 | title | Two mutations affecting conserved residues in the Met receptor operate via different mechanisms | |
| P478 | volume | 19 |
| Q112053038 | Advances in Renal Cell Carcinoma Drug Resistance Models |
| Q40070648 | Biological role of the HGF/MET ligand/receptor couple in bovine mammary epithelial cells. |
| Q34002709 | Cancer driver mutations in protein kinase genes |
| Q30374663 | Computational modeling of structurally conserved cancer mutations in the RET and MET kinases: the impact on protein structure, dynamics, and stability. |
| Q42825226 | Differential requirement of the last C-terminal tail of Met receptor for cell transformation and invasiveness. |
| Q38735120 | Exon 14 Deleted MET Receptor as a New Biomarker and Target in Cancers. |
| Q44226606 | Gain of function mutations of RTK conserved residues display differential effects on NTRK1 kinase activity. |
| Q55285319 | Hypoxia leads to decreased autophosphorylation of the MET receptor but promotes its resistance to tyrosine kinase inhibitors. |
| Q36868642 | Initial Clinical Sensitivity and Acquired Resistance to MET Inhibition in MET-Mutated Papillary Renal Cell Carcinoma |
| Q28214703 | K252a inhibits the oncogenic properties of Met, the HGF receptor |
| Q38445359 | NPS-1034, a novel MET inhibitor, inhibits the activated MET receptor and its constitutively active mutants |
| Q40456936 | RNAi technology and lentiviral delivery as a powerful tool to suppress Tpr-Met-mediated tumorigenesis. |
| Q33510934 | Sequence and structure signatures of cancer mutation hotspots in protein kinases |
| Q24307789 | Structural characterization of autoinhibited c-Met kinase produced by coexpression in bacteria with phosphatase |
| Q38297235 | Targeting the MET pathway for potential treatment of NSCLC. |
Search more.